Formycon Partners With Leukocare For Stable Biosimilar Formulations

Formycon Has Three Biosimilars In Advanced Development

 
• By Dean Rudge

Achieving superior stability profiles, leading to additional value propositions for development projects, is the aim of the game for Formycon and Leukocare under a new strategic development agreement.

Handshake of businessmen
Leukocare will apply its formulation and bioinformatics expertise to Formycon’s “comprehensive development knowhow.” • Source: Shutterstock

More from Biosimilars

More from Products